Category Archives: Clay Siegall

Seattle Genetics: A Leader in the Development of Antibody-Drug Conjugate

Seattle Genetics is a biotechnology company that develops and commercializes monoclonal antibody-based therapies to treat cancer, autoimmune ailments, and other acute medical conditions. The biotechnology company is an industry leader in developing antibody-drug conjugates (ADCs), a technology used to harness the targeting capability of monoclonal antibodies to inject cell-killing agents to cancer cells. The biotechnology… Read More »